Author

T. Milde

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Assay:scRNA-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. Korshunov· 2 shared A. Rademacher· 2 shared A. Wittmann· 2 shared B. Jones· 2 shared B. Statz· 2 shared C. M. van Tilburg· 2 shared D. T. W. Jones· 2 shared F. Westermann· 2 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Korshunov

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell-state plasticity drives heterogeneity in Group 3/4 medulloblastoma

P. Joshi, P. B. G. da Silva, K. Okonechnikov, T. Stelzer, I. Sarropoulos, M. Sepp, J. Nolle, M. V. Pour-Jamnani, A. Rademacher, T. Yamada, C. Schneider, J. Schmidt, L. Bianchini, P. Schaefer, K. Leiss, , L. M. Kutscher

This study identifies cell-state plasticity as a driver of heterogeneity in Group 3/4 medulloblastomas, showing that transcription factor perturbation can redirect tumor cells along different differentiation trajectories.

bioRxiv · Feb 9, 2024 · PreprintCancer Biology

Medulloblastoma oncogene aberrations are not involved in tumor initiation, but essential for disease progression and therapy resistance

K. Okonechnikov, P. Joshi, V. Koerber, A. Rademacher, M. Bortolomeazzi, J.-P. Mallm, P. B. G. da Silva, B. Statz, M. Sepp, I. Sarropoulos, T. Yamada-Saito, J. Vaillant, A. Wittmann, K. Schramm, M. Blattner-Johnson, , S. M. Pfister

The paper uses single-cell technologies to show that large-scale chromosomal aberrations drive medulloblastoma initiation, while single-gene oncogenic events like MYC contribute to progression and therapy resistance.

bioRxiv · Feb 9, 2024Cancer Biology

A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis

U. Khalid, M. Simovic, M. Iskar, J. K. L. Wong, R. Kumar, M. Jugold, M. Sill, M. Bolkestein, T. Kolb, M. Hergt, F. Devens, J. Ecker, M. Kool, T. Milde, F. Westermann, , A. Ernst

The paper identifies a synergistic effect between HDAC and PARP inhibitors in childhood tumors with chromothripsis, validated through drug screening and in vivo models.

bioRxiv · Apr 22, 2021Cancer Biology